Shares in Theralase Technologies Inc (CVE:TLT, OTCMKTS:TLTFF) were lifted 4% on Tuesday as there was more good news for its lead cancer compound TLD-1433, which has been shown to destroy certain lung cancers.
The drug is what's called a light activated photo dynamic compound (PDC), and is also currently being studied in a bladder cancer trial.
This latest data comes from pre-clinical research carried out by Dr Kazuhiro Yasufuku and his team in Toronto on its affect on lung squamous cell carcinoma, large cell lung cancer carcinoma and lung adeno carcinoma, all of which are non-small cell lung cancers (NSCLC), which accounts for 85% of all cases of the killer disease.
The study showed that TLD-1433, when combined with transferrin to form Rutherrin can localize to and destroy the various forms of lung cancer - in test tubes and live model experiments.
In simple terms, this is because it can attach itself to transferrin receptor (Tf-R), which is prevalent in cancer growth, and not affect healthy tissue.
"These results support the hypothesis that safety and efficacy of PDT therapy will be enhanced due to improved localization to lung tumours versus healthy lung tissue and the selective irradiation of the cancer lesions by strategic placement of the laser light source," said Dr Yasufuku.
"The selectivity data also suggests that when an efficacious level of Rutherrintrademark is delivered and then light activated, a high kill rate of lung cancer may be achieved in patients. This hypothesis will be tested in future preclinical work using orthotopic animal models and if successful, then tested clinically in a Phase Ib human NSCLC clinical trial."
A delighted Roger Dumoulin-White, Theralase chief executive, added: "The quality of this research lays the ground work for further preclinical experiments and if proven successful the commencement of a Phase Ib clinical study for NSCLC, the leading cause of cancer related death."
Shares gained 4.35% to C$0.48.